Cancer

Autonomix Medical, Inc. Announces Pricing of $5.0 Million Private Placement Priced At The Market Under Nasdaq Rules

THE WOODLANDS, TX, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical…

3 months ago

Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer

RAD 402 is a humanized IgG1 internalized by prostate cells, binding KLK3 with high affinity Tb-161 antitumor activity driven by…

3 months ago

Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America

OncoVanguard8 is a leading service provider for innovative healthcare products for insurance companies operating in Peru, Colombia and EcuadorBERKELEY, Calif.…

3 months ago

INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference

Boca Raton, FL, Nov. 18, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company,…

3 months ago

CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India

SINGAPORE, Nov. 18, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical…

3 months ago

ProPhase Labs, Inc. to Present Third Quarter 2025 Financial Results on November 19

UNIONDALE, NY, Nov. 18, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation…

3 months ago

Anavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025

Webcast and Conference Call To be Held Tuesday, November 25, 2025, 8:30 am ETNEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE)…

3 months ago

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

Three BriaCell poster presentations include updated key biomarker data from BriaCell’s pivotal Phase 3 study and updated survival data from…

3 months ago

HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease

First Patient Dosed at The Ohio State University Wexner Medical Center in this Multi-Center Trial Active component of HCW9302 is…

3 months ago

EDAP to Present at Piper Sandler 37th Annual Healthcare Conference

EDAP to Present at Piper Sandler 37th Annual Healthcare Conference Company to Present and Host 1x1 Investor Meetings on Tuesday,…

3 months ago